Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Allogene Therapeutics

Allogene Therapeutics
2017 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
ALLO STOCK SYMBOL
$28.01 SHARE PRICE (As of Friday Closing)
Description

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Primary Office
  • 210 East Grand Avenue
  • South San Francisco, CA 94080
  • United States

+1 (415) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Allogene Therapeutics’s full profile, request a free trial.

Allogene Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$21.67 - $35.55 $3.4B $28.24 -$1.97 470K 122M

Allogene Therapeutics Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
Enterprise Value 3,463,732
Revenue 0 0
EBITDA (245,722) (212,553)
Net Income (239,089) (211,199)
Total Assets 749,369 773,855
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Allogene Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Allogene Therapeutics‘s full profile, request access.

Request full access to PitchBook

Allogene Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Allogene Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Allogene Therapeutics Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aileron Therapeutics Formerly VC-backed Watertown, MA 00 00000 000000000 00000
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
000000000 Venture Capital-Backed Paris, France 000 00000 00000000 00000
00000 Formerly PE-Backed Paris, France 00 00000 00000000000 00000
0000000 000 Corporation New York, NY 00 0000 00000000 0000
To view this company’s complete list of competitors, request access »

Allogene Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Allogene Therapeutics‘s full profile, request access.

Request full access to PitchBook

Allogene Therapeutics Executive Team (7)

Name Title Board
Seat
Contact
Info
David Chang Ph.D Co-Founder, President, Chief Executive Officer & Board Member
Eric Schmidt Ph.D Chief Financial Officer
Alison Moore Ph.D Chief Technology Officer
Barbra Sasu Ph.D Chief Scientific Officer
Christine Cassiano Chief Communications Officer
You’re viewing 5 of 7 executives. Get the full list »

Allogene Therapeutics Board Members (10)

Name Representing Role Since Contact
Info
Arie Belldegrun MD Self Co-Founder & Executive Chairman 000 0000
David Bonderman JD Self Board Member 000 0000
David Chang Ph.D Allogene Therapeutics Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Deborah Messemer Allogene Therapeutics Board Member 000 0000
Franz Humer Ph.D Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »